Stock Price
21.34
Daily Change
2.15%
Yearly
-45.71%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 132.49 -0.54 -0.41% 19.51%
Agenus 2.68 -0.06 -2.19% -22.09%
Agios Pharmaceuticals 29.80 -0.56 -1.84% -37.22%
Achaogen Inc. 0.03 0 0% 108.33%
Ardelyx 0.84 -0.04 -4.60% -88.32%
Bluebird Bio 7.24 0.31 4.47% -84.48%
BioMarin Pharmaceutical 84.65 0.20 0.24% -3.80%
Celldex Therapeutics 27.87 -1.29 -4.42% 56.57%
Chimerix 5.51 -0.07 -1.25% -40.63%
Curis 3.07 -0.08 -2.54% -71.99%
Emergent BioSolutions 47.13 0.61 1.31% -56.00%
Epizyme 2.07 -0.12 -5.48% -81.92%
Intercept Pharmaceuticals 15.41 -1.59 -9.35% -47.69%
Incyte Corp 74.96 0.20 0.27% -23.42%
Life Technologies 5.99 -0.31 -4.92% 52.81%
Eli Lilly 243.46 0.33 0.14% 18.10%
MacroGenics 12.71 -0.19 -1.47% -43.64%
Novartis 79.78 -1.61 -1.98% -7.16%
Novartis 87.03 -1.16 -1.32% -10.17%
Pfizer 52.88 -1.17 -2.16% 44.68%
Prothena 35.23 -0.20 -0.56% 158.85%
Regeneron Pharmaceuticals 616.93 2.55 0.42% 14.72%
Teva Pharmaceutical Industries 8.51 -0.13 -1.50% -32.19%
Xoma 21.34 0.45 2.15% -45.71%

Indexes Price Day Year
NASDAQ 13769 -385.10 -2.72% 1.67%
US2000 1988 -36.12 -1.78% -8.34%

Xoma
XOMA Corporation (XOMA) is a biotechnology royalty aggregator. The Company's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that is licensed to pharmaceutical or biotechnology companies. Its product candidates include PTH1R, a G-protein-coupled receptor involved in the regulation of calcium metabolism; XMetA, an insulin receptor-activating antibody, and X213, an allosteric inhibitor of prolactin action. It has a range of antibody discovery and development technologies, which includes antibody discovery advanced platform technologies (ADAPT), ModulX and OptimX. The ADAPT technology includes phage display libraries integrated with yeast and mammalian display. Its ModulX technology enables the identification of allosteric antibodies for positive or negative modulation of biological pathways. The OptimX technology is used for optimizing biophysical properties of antibodies.